Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They are short and want to detour potential buyers. Period! They spend all day bashing and say they are sick and tired of Gerald and manf and dilution when they actually live anything they can grasp on to point out negative perception. Truth is we control the dilution (which will occur in any bio) by the price which we sell. The things ambs has accomplished in the past few years is remarkable. We are way under valued. Let's hold and force a short squeeze!
This is outstanding! Great milestone and very attractive to big pharma and institutional guys. This paired with the Regenicin news are game changers alone. AMBS is going to run-hold your shares so the sorts can't cover as easily.
I still have a few hundred thousand shares and am planning on holding. My due diligence still shows this as a strong buy.
I thought we wouldn't hear anything until after the 3 months?
Why the hard drop?
They have lawsuit insurance so it won't impact us as shareholders at all.
I gobbled up call options :)
Hope for hiv drug approval and we hit 120 next week :)
Is now the time to buy?
Let's take a look at some of the fundamentals behind Amarantus and some technical issues as far as trading. Today's news was huge for AMBS. Basically stating that data was strong enough preliminarily to execute an option and take the data and create an outline for a clinical trial. The current analyst, Jason Napadano, is giving very little consideration in his price reflection for MANF until they are ready to put manf into a clinical trial. Well it seems like the company is positioning to do just that. Remember that the big deal with targeting Retinitas pigmentosa is that most likely AMBS will file for an orphan indication. The filing alone will be a value inflection. If the data is good and the trial is well put together then there is no reason that we shouldn't receive fast track designation (another value inflection).
Now let's take a technical look at the stock and put the puzzle together mixed with potential short term catalyst. The market was waiting for data for the anticipated lympro sets. The anticipation pushed the stock to almost .20 a share on high volume. The data that came out was a small population and was statistically significant enough to so that there was a difference between the control and the treatment group. The market did not understand the data and there was a sell off. The overselling was actually into very promising and a great data set. Technically we are in the .10 range and on today's open we had a few hundred thousand shares traded. Out of no where sellers sold 6 million shares in a matter of minutes and the market absorbed the shares with very little downward movement. This technically shows that currently it should remain at minimum this price. Now let's mix the fundamentals with the technicals. We have a floor and know that the front line data was great and ambs is over subscribing the trial. This shows confidence in management in the front line information. Remember the market sold based on misunderstanding these findings. So why would management take a chance with the oversubscription? Well the more people in the study the more risk but also the more opportunity for a reward. AMBS has stated that they are in talks with a negotiation for a partnership. By being over subscribed this will increase the value if the numbers are what management believes they will be. Huge confidence sign. We know that the results will come out between now and the next few weeks and that ambs most likely will each a partnership almost immediately after.
Remember we are also anticipating projections for lympro along with the start of eltropozine in the phase 2b. All of which management has indicated that they are going to be gearing for an uplist to a national exchange.
Buckle up
OPHC is now profitable and no one knows about them- I'm in!!! I plan on holding this for a few years given what the new leadership has accomplished in such a short amount of time and their track record. GLTA
They have enough cash to make it through first q 2016. Also their market cap is way undervalued giving the potential for annual sales is over $500mm. Not to mention that there are only 70 places in America that do the majority of the spinal surveys showing that NVIV will be able to reach almost everyone who would administer the product in a very short time frame. We aren't looking to heal people who are paralyzed (even though that would be amazing) but looking to improve body function and quality of life. Primary point we are looking for once the first patient is enrolled (which isn't a question of if but when) is the safety of the device. If that comes back good (which all pre human study's came back with great safety indications) then we will see a share price pop significantly. We will also see the next enrollment with NVIV approaching the FDA to speed up the study by enrolling more then 1 patient at a time. This could be a game changer and the price is going into our short term favor. Imo
Thank you sir. Trust me, we have a few million dollars in this thing and understand the risk associated with it. The short interest in this board have done a great job creating doubt but it is evident that AMBS has done amazing positioning the company for success!
Sorry for a few sentence fragments... Typed this from my phone :(
Alright, let's recap- in just a short time AMBS went from owning a small IP portfolio on MANF to where we are today. So where are we exactly? Right now our CEO is amongst the world's elite in the Alzheimer's space. We have a diagnostic which is in the running to be the first blood diagnostic in this space. We are still on track to be commercialized this year for trials. This is a stepping stone for the world market. By gaining accreditation with the trails will gain not only exposure but acceptance within the health care space. By just being in the middle of this conference the main players are taking note. It's not time to expose the agenda just yet. Why? Well in the middle of the conference is also big pharma (where we all will make our money from AMBS- I mean real money). Gerald has managed to be in the same room as them for years now. At first he was not known and was paid no attention to. Now these guys are seeing him build from what was a meek IP portfolio to it being way more extensive. They have seen a progression. He now has a diagnostic which is being primed for other applications. He has acquired a phase 2b drug. Positioning the study to be submitted, Identified reimbursement codes, putting together applications for various orphan designations, aligning a program diabetes, set up alliances with key incubator's which will not only develop MANF and Lympro but identify future therapies and technologies, moved the lab to Jansen (huge), opened up Geneva offices, solidified a powerful board of directors, has 18 employees working to further develop the plan, has cash in the books, access to $20 million more dollars and will receive an additional $5 million dollars in new warrant proceeds. Remember in the filings a bit ago when JP Morgan mentioned they may now buy in addition to another major fund making the same declaration? People are paying attention. He now is in the middle of the world's elite including big pharma and they all see what he has done. He is in talks for a partnership which he has publicly stated. Imagine if he would of done a partnership a year ago. How much shareholder would have been lost? Jason napadano has a price target of .20. This does not include eltropozine or the orphan application or reimbursement or a partnership, or a diabetes program. Some expectations that we have are off- not solid thinking... Would be like telling the other team what you are about to call. The price isn't down because of the conference, it is down because we are selling!
Yes! Very important-
That's just the upfront cash. The partnership will pay millions to advance lympro and support bringing it to the market.
$1.5 to $3mm upfront cash- but will pay the millions needed to advance lympro. Set the proper expectations so when announced it will not be a negative but positive announcement. Understanding the huge value even with 1.5 to 3mm upfront.
I wish there would be substantial cash but that isn't the case. The partnership will be huge in respect that they will pay and support the development of lympro. Huge money but more on the back end... Not up front cash.
I believe IMO that people shouldn't be expecting a big up front payment from a big pharma, but should be happy with the stamp of approval from a BP. Investors have to remember that whoever is our partner will be taking on a lot of the expenses making the test, cost of marketing, and up front equipment, and employees working with us. The value is not in the upfront payment, but the longevity of the BP bringing in revenue and making Lympro the gold standard.
I guess you did want to be short
I'm not. I talked to him. He said it doesn't effect the uplist at all. The only thing it changes is he has to file a s1 and he can't file an s3. Which doesn't matter because he doesn't need to raise money besides drawing on the equity line when the price spikes so they can get eltropozine to the next phase studies. He said the biggest thing it has been is an embarrassment. Sometimes things happen outside your control and it was just a mistake. In a weird way it helps us because now they will have to be even more transparent which they already have done a good job of that.
He said it did not.
Nice confirmation on an update on lympro from Gerald coming Monday. Doc nice call.
Great article by David today!!
Wow, someone bought over 230,000 shares at $390 a share!!!
That has always been the focus but you have to be able to remove the obstacles that stand between you and the goal. A big obstacle has always been cash and now they are in position.
That tells me that he is confident he will be hitting milestones that will raise the pps before he reverses and up list.
That's the beauty. Gerald doesn't have to do anything quick anymore. They have enough money now and can be focused on results and being pin point accurate.
He is right- institutional investor have been following AMBS and have not been able to buy until the financials are in line. This starts to enable some institutions to buy and up listing will allow many more to come in as well. We should be noticing higher volume if this is the case and an upward trend due to those shares not being swing traded. Also like the fact that AMBS was able to take in 400k above market at $0.10 for the first traunch of the equity line. One thing to consider is that the potential dilution is well worth it. If I said that we would be giving up an additional 200mm shares for 20mm then people would be livid. However, the fact is AMBS controls when they take in money and because they have current cash on hand and are not going to need to draw down on the equity line anytime soon, there will be far less dilution. In fact that dilution in a sense only matters now if they are successful. Because now the play is advancing the company. It's almost like AMBS just raised $20mm at $0.50 a share or better. Next point is that this money is equity dilution. That means that with the money and dilution from it, the company will be able to add value higher for pps by having it. The ability to get MANF into clinicals , get our phase 2b trial started, commercialize lympro and look at other acquisitions will leave us at a way better pps. Orphan status is huge and we are finally in a great position to be given a grant now that they know we aren't going anywhere. According to Jason he is giving us a target of $0.25 pps without taking this financing into consideration or without taking the phase 2b in consideration. I would expect a higher target and Jason, would love to see at the end of your write up...not only a strong buy but saying that you just bought a ton of share yourself.
A lot of you have said some harsh things about Gerald over these boards. I think a few of you should apologize. The man works around the clock period and has done a great job.
This is a huge deal! Not only is this a mega potential revenue stream but this is another vehicle to provide ambs with the ability to Fund all the programs. The organization that sold this asset would only sell if conditions were set and they were confident the company would be able to afford the cost associated with development. They would have royalties and would condition the deal around ambs's ability. This also creates another direction for further grants and brings the MJFF to donate more money then previous commitments. Let's not forget the orphan indicators application should be back soon and Dr. Urano has great connections and has already received millions in grants. This also is a potential treatment for diabetes. Once (not if) the warrants get executed AMBS will have enough money to execute and be in a position where they have multiple bullets in the barrel when negotiating a JV or partnership because it will be a negotiation of strength not desperation. IMO
Yes. What is the short position? Great question. Can you say squeeze!!!!!!
I remember I got laughed at for my post a bit ago. Lol
Isn't results from a rest suppose to be given this week? Does anyone know?
I'm in! Go pphm gogogogogo
I think ambs is a great play. I remember I came across a professional Japanese basketball player once who thought sorting this stock would cause infectious dissolution of the pps. Can't believe he was right. Go figure.
Buckle up